Clinical Trial Update: A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update describing safety, tolerability, and imaging with [68Ga]Ga-DPI-4452 and safety, tolerability, and efficacy with [177Lu]Lu-DPI-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Muscle-invasive Bladder Cancer
• Pancreatic Ductal Adenocarcinoma
• Squamous Cell Carcinoma of the Lung
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• [177Lu]Lu-DPI-4452 (DPI-4452)
• [68Ga]Ga-DPI-4452 (DPI-4452)

Snippet

Sponsor: ITM Oncologics GmbH | Conditions: Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1, Phase 2 | Status: RECRUITING